Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient
- PMID: 8970360
- DOI: 10.1164/ajrccm.154.6.8970360
Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient
Abstract
Post-transplantation lymphoproliferative disorder (PTLD) is a widely recognized and often catastrophic complication of organ transplantation. The incidence of PTLD after lung transplantation ranges from 6.2 to 9.4% and is two-fold higher than that seen after organ transplantation of other organs. Primary Epstein-Barr virus (EBV) infection is a major risk factor for PTLD, but the incidence of PTLD in EBV seronegative (EBV-) patients seems to vary with type of organ transplant. The goal of this study was to quantify the risk of PLTD based on pre-lung transplantation EBV serostatus in lung transplant patients. Pre- and post-lung transplant serostatus was defined in 80 patients, and our six cases of PTLD occurred in this group. Six of 94 lung transplant patients (6.4%) who survived > 1 mo developed PTLD. All cases of PTLD involved thoracic structures at presentation and occurred in the first post-operative year. Patients who were EBV- before lung transplant were much more likely to develop PTLD than those who were seropositive (EBV+) (five of 15 [33%] versus one of 60 [< 2%], p < 0.001). Consistent with the prevailing adult (donor) EBV+ rate (85%), two of our EBV-patients remained EBV-after lung transplant. Therefore, the rate of PTLD was 42% in those with primary EBV infection. As compared with EBV-patients that remained tumor-free, those who developed PLTD had similar levels of immunosuppressants and doses of anti-viral therapy. We conclude that PLTD occurs predominantly in EBV-naïve patients (risk approximately 1/3). EBV-patients should be monitored more closely after lung transplantation and, possibly, managed with lower immunosuppression. Our data also suggest that anti-viral therapy alone does not decrease the incidence of PTLD in high risk patients, PTLD can be successfully treated in most cases, and EBV-naïve patients should not be excluded from lung transplant because their risk of death from PTLD is < 15%.
Similar articles
-
Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.Transpl Infect Dis. 2005 Sep-Dec;7(3-4):133-6. doi: 10.1111/j.1399-3062.2005.00110.x. Transpl Infect Dis. 2005. PMID: 16390402
-
Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.Transpl Infect Dis. 2016 Jun;18(3):423-30. doi: 10.1111/tid.12533. Epub 2016 May 23. Transpl Infect Dis. 2016. PMID: 27016725
-
Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.Ann Thorac Surg. 2018 Feb;105(2):441-447. doi: 10.1016/j.athoracsur.2017.09.033. Epub 2017 Dec 7. Ann Thorac Surg. 2018. PMID: 29223419
-
Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.Transpl Infect Dis. 2001 Sep;3(3):177-85. doi: 10.1034/j.1399-3062.2001.003003177.x. Transpl Infect Dis. 2001. PMID: 11493400 Review.
-
[Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].Nefrologia. 2002;22(5):463-9. Nefrologia. 2002. PMID: 12497748 Review. Spanish.
Cited by
-
Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.Pediatr Cardiol. 2015 Dec;36(8):1748-53. doi: 10.1007/s00246-015-1229-y. Epub 2015 Jul 18. Pediatr Cardiol. 2015. PMID: 26187515
-
Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Semin Respir Crit Care Med. 2015 Apr;36(2):299-320. doi: 10.1055/s-0035-1547347. Epub 2015 Mar 31. Semin Respir Crit Care Med. 2015. PMID: 25826595 Free PMC article. Review.
-
Donor infection: an opinion on lung donor utilization.J Heart Lung Transplant. 2005 Jul;24(7):791-7. doi: 10.1016/j.healun.2004.05.007. J Heart Lung Transplant. 2005. PMID: 15982604 Free PMC article. Review. No abstract available.
-
Viral infections in lung transplantation.J Thorac Dis. 2021 Nov;13(11):6673-6694. doi: 10.21037/jtd-2021-24. J Thorac Dis. 2021. PMID: 34992844 Free PMC article. Review.
-
Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.Thorax. 2006 Jun;61(6):507-13. doi: 10.1136/thx.2005.049247. Epub 2006 Apr 6. Thorax. 2006. PMID: 16601086 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials